ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

3:00PM-4:30PM: Abstract Number: 1585

Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)

Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

3:00PM-4:30PM: Abstract Number: 1587

Efficacy and Safety of Curcumin in Maintaining Remission During Disease Modifying Anti Rheumatic Drug Withdrawal in Rheumatoid Arthritis at 52 Weeks: Phase III Double-Blind Randomized Placebo Controlled Trial

Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

3:00PM-4:30PM: Abstract Number: 1593

Epidemiology and Outcomes of Infection-related Hospitalizations in Young Adults with SLE: Data from National Inpatient Sample

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

3:00PM-4:30PM: Abstract Number: 1601

Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial

Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA

3:00PM-4:30PM: Abstract Number: 1602

Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis

Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA

3:00PM-4:30PM: Abstract Number: 1594

Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

3:00PM-4:30PM: Abstract Number: 1589

Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis

Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

3:00PM-4:30PM: Abstract Number: 1588

Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Use of Adalimumab in Patients with Rheumatoid Arthritis

Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

3:00PM-4:30PM: Abstract Number: 1591

Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

3:00PM-4:30PM: Abstract Number: 1590

Pain and Treatment Switching Among Patients in the CorEvitasTM Rheumatoid Arthritis Registry

Abstracts: RA – Treatment I: Switching or Discontinuation of Therapies

3:00PM-4:30PM: Abstract Number: 1580

Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout

Abstracts: Metabolic and Crystal Arthropathies – Basic and Clinical Science

3:00PM-4:30PM: Abstract Number: 1581

Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study

Abstracts: Metabolic and Crystal Arthropathies – Basic and Clinical Science

3:00PM-4:30PM: Abstract Number: 1583

Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial

Abstracts: Metabolic and Crystal Arthropathies – Basic and Clinical Science

3:00PM-4:30PM: Abstract Number: 1598

Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA

3:00PM-4:30PM: Abstract Number: 1592

Serious Infections in SLE- Incidence, Associated Factors, Impact and Trends over Two Decades

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].